Abivax CEO stated to CNBC that the company is not rushing for a deal, confident that key June trial data will enable them to secure better terms for potential partnerships, amidst analyst speculation of a takeover, reiterating no urgency for deal-making ahead of the readout.

Abivax stock saw its gains reduced after the company denied speculation regarding a potential deal or collaboration with AstraZeneca.

Abivax has announced its full-year financial results, providing an overview of the company's performance.

An analysis outlines two key reasons why Abivax stock is projected to achieve a tenfold increase in value by the year 2036.

Eli Lilly is reportedly considering re-entering the bidding process for Abivax, contingent on whether AstraZeneca fails to meet its acquisition deadline.